Beaumont G
J Int Med Res. 1977;5(1 Suppl):37-44.
An attempt was made to measure the effects of depressive illness and of clomipramine (Anafranil) therapy in doses of 30 mg and 75 mg daily on sexual appetite and performance. A special questionnaire was devised to gather information on sexual habits before illness, during illness and following treatment. It proved difficult to differentiate between the beneficial effects of recovery from depression and the possible adverse drug effects on sexual activity. Two patients dropped out of the study because of supposed sexual side-effects--a male with ejaculatory difficulties and a female with orgasmic impotence. Fifty-four patients completed the sexual questionnaire and a four-week course of clomipramine. There were nineteen males and thirty-five females. Sixty-eight per cent of males and 57% of females had their 'sex life' impaired by depressive illness. Coital rate was decreased and depression interfered with performance and satisfaction. Clomipramine therapy seemed to have advantageous and disadvantageous effects. The advantageous effects were probably associated with improvement in depressive illness. There was evidence that clomipramine had an adverse effect sexually in 26% of males and 14% of females. The effect was dose-related in females.
研究尝试测量抑郁症以及每日服用30毫克和75毫克氯米帕明（安拿芬尼）治疗对性欲和性功能的影响。设计了一份特殊问卷，以收集患病前、患病期间及治疗后的性行为习惯信息。事实证明，很难区分抑郁症康复的有益效果与药物对性活动可能产生的不良影响。两名患者因疑似性副作用退出研究，一名男性有射精困难，一名女性有性高潮障碍。54名患者完成了性问卷和为期四周的氯米帕明疗程。其中有19名男性和35名女性。68%的男性和57%的女性的“性生活”因抑郁症受损。性交频率降低，抑郁症影响了性表现和满意度。氯米帕明治疗似乎有有利和不利影响。有利影响可能与抑郁症病情改善有关。有证据表明，26%的男性和14%的女性在性方面受到氯米帕明的不良影响。女性的这种影响与剂量相关。
